EPA:DHA 6:1 prevents right ventricular dysfunction and lung vascular remodeling in monocrotaline-induced pulmonary arterial hypertension in rats by mitigating inflammatory and pro-oxidant responses

18 May 2025 (15:00 - 15:45)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Said AMISSI

University of Strasbourg, Strasbourg (France)

4 More presentations in this session

Presentation thumbnail

Left ventricular reverse remodeling in heart failure with reduced ejection fraction: determinants and outcomes in a multidisciplinary heart failure clinic in a resource limited setting

Doctor B. Chung (Kuching, MY)

Abstract Slides Video

Presentation thumbnail

Echocardiographic parameters in patients with right heart failure and sarcopenia.

Doctor M. Hernandez Hernandez (Mexico City, MX)

Abstract Slides Video

Presentation thumbnail

Cardiac reverse remodeling after SGLT2 inhibitor therapy: exploring beyond sex differences

Doctor S. Prosperi (Rome, IT)

Abstract Slides Video

Presentation thumbnail

Multiparametric approach to predict long-term survival in ischemic heart failure patients undergoing surgical ventricular reconstruction

Doctor G. Guida (San Donato Milanese, IT)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiac remodeling across the ejection fraction spectrum

The Event

Event poster

Heart Failure 2025

18 May 2025 15:00 CET

You may be interested in

Congress Presentation

Circulating low-grade inflammation in human pulmonary arterial hypertension promotes eNOS-NO/ROS imbalance: Involvement of the angiotensin and the endothelin pathways and prevention by EPA:DHA 6:1

Congress Presentation

Colchicine as a therapeutic option for the treatment of pulmonary arterial hypertension (PAH) in a rat model

Congress Session

Molecular approaches to the treatment of pulmonary hypertension

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources